As a D-amino acid peptide, FOXO4-DRI is costly to synthesize, and a wrong amino acid at the binding site can sharply cut activity
Key Features High-purity lyophilized peptide Batch-specific Certificate of Analysis included Manufactured under strict quality standards Suitable for controlled laboratory research Packaged for professional handling environments Technical Specifications Compound: BPC-157 Format: Lyophilized powder Strength: 10 mg per vial Purity: 9899% (COA included) Appearance: White powder Category: Research peptide reagent Intended Use This product is intended strictly for: Laboratory research In-vitro studies Biochemical analysis Preclinical model research Not intended for: Human or animal use Injection, ingestion, inhalation, or topical application Medical, therapeutic, diagnostic, or cosmetic purposes This compound is not approved by Health Canada or any regulatory authority for clinical use
Wellness injections are administered using small needles and are generally very well tolerated
Over time, researchers noticed that levels of GHK-Cu tend to decrease with age, which led to further interest in how it relates to skin appearance
KPV, the C-terminal -MSH fragment, modulates NF-B signaling and inflammatory-cytokine response in cell-based models
PMC 4145307